References
- Ko YT, Bhattacharya R, Bickel U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Release 2009;133:230–7
- Fischer D, Bieber T, Li Y, et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999;16:1273–9
- Kunath K, Von Harpe A, Fischer D, et al. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release 2003;89:113–25
- Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894–9
- Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002;6:67–72
- Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood--brain barrier transferrin receptor. J Pharmacol Exp Ther 2005;313:1075–81
- Von Harpe A, Petersen H, Li Y, et al. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J Control Release 2000;69:309–22
- Ko YT, Bickel U, Huang J. Polyethylenimine/oligonucleotide polyplexes investigated by fluorescence resonance energy transfer and fluorescence anisotropy. Oligonucleotides 2011;21:109–14
- Bhattacharya R, Osburg B, Fischer D, et al. Targeted delivery of complexes of biotin-PEG-polyethylenimine and NF-kappaB decoys to brain-derived endothelial cells in vitro. Pharm Res 2008;25:605–15
- Wang J, Tian S, Petros RA, et al. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc 2010;132:11306–13
- Juliano RL, Carver K, Cao C, et al. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J Drug Target 2013;21:27–43
- Cameron PL, Ruffin JW, Bollag R, et al. Identification of caveolin and caveolin-related proteins in the brain. J Neurosci 1997;17:9520–35
- Khawli LA, Prabhu S. Drug delivery across the blood--brain barrier. Mol Pharm 2013;10:1471–2
- Iwasa A, Akita H, Khalil I, et al. Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. Biochim Biophys Acta 2006;1758:713–20
- Kreuter J. Mechanism of polymeric nanoparticle-based drug transport across the blood--brain barrier (BBB). J Microencapsul 2013;30:49–54
- Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res 2010;27:1759–71
- Van Rooy I, Mastrobattista E, Storm G, et al. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release 2011;150:30–6
- Qian ZM, Li H, Sun H, et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561–87
- Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000;97:7567–72
- Shi N, Zhang Y, Zhu C, et al. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 2001;98:12754–9
- Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65–81
- Bickel U, Kang YS, Yoshikawa T, et al. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 1994;42:1493–7